Comprehensive Translational Medicine
CDO Enabling Drug R&D
A Leader of Companion Diagnostics Total-Solution Providers
Patient Testing for Precision Medicine
State-of-Art Facilities & Global-standard Quality Systems
Translational Medicine
MEDx Translational Medicine Co., Ltd (simply MEDx) was founded in 2013, formerly known as QIAGEN (Suzhou) Translational Medicine Co., Ltd.Obtained with comprehensive technology platforms, high quality system, and strong IVD R&D experience, MEDx has become a leading innovative company in companion diagnostics and the total solution provider for precision medicine in China.
Taking advantage of the comprehensive translational platforms including genomics, proteomics, cytomics, and pathology, MEDx offers integrated solutions from biomarker discovery, target validation, molecular testing, and patient stratification for drug clinical trials, to the IVD/CDx R&D and commercialization. With a world-class technical team and a rich IVD/CDx pipeline, MEDx collaborates with hundreds of world-renowned pharmaceutical companies.
We are honored to invite you to participate in the Medlab Asia & Asia Health, which will take
Time:5-8 February, 2024Address:Dubai World Trade CentreMEDx Booth No: # Z2.H19We are honored
Introduction The study of cancer has been extended from single genes to macrogenes, and from sing
view more >>
view more >>
view more >>
view more >>
Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cance
Kura Oncology won FDA priority review for its drug the day before announcing new data at ASCO 2025 s
Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for th
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-
A research team has developed a new class of compounds that effectively inhibit both wild-type CDK9
Carnegie Mellon University researchers are using personalized models to decode how cancer behaves in
A study led by University of Cincinnati Cancer Center researchers sheds new light on the mechanisms
Researchers have identified C5aR1 as a novel biomarker for metastasis risk and poor prognosis in pat